Pure Global
CDSCO UID IMP/IVD/2020/000304_042c7727aefb19ff73b26f73740faa14_f6ed894c3bcb8d87160ef8d745f94add

qSARS-CoV-2 IgG/IgM Rapid Test

Concept Healthcare·Device Class Class C·India CDSCO·Brand: Cellex
Registration details
UID
IMP/IVD/2020/000304_042c7727aefb19ff73b26f73740faa14_f6ed894c3bcb8d87160ef8d745f94add
Device class
Class C
Brand name
Cellex
License holder
Concept Healthcare
Approving authority
CDSCO
Product information
The qSARS-CoV-2 IgG/IgM Rapid Test is intended for rapid and qualitative detection of antibodies indicative of SARS-CoV-2 infection and used as an aid for diagnosis of SARS-CoV-2 infection.
Similar products (1)
Other products with the same name or brand
Cellex qSARS-CoV-2 IgG/IgM Cassette Rapid Test
Brand: Cellex
Inbios India
Class C
About this record

qSARS-CoV-2 IgG/IgM Rapid Test is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2020/000304_042c7727aefb19ff73b26f73740faa14_f6ed894c3bcb8d87160ef8d745f94add. This device is marketed under the brand name Cellex. The license holder is Concept Healthcare, and it is classified as Device Class Class C. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.